Protective effects of quinaprilat and trandolaprilat, active metabolites of quinapril and trandolapril, on hemolysis induced by lysophosphatidylcholine in human erythrocytes

Biological and Pharmaceutical Bulletin

Volumn 26, Issue 5, 2003, Pages 712-716

  Hayase, Nobumasa ^a   Satomi, Machiko ^a   Hara, Akiyoshi ^a   Awaya, Toshio ^a   Shimizu, Keiko ^a   Matsubara, Kazuo ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Hemolysis, lipophilicity; Lysophosphatidylcholine

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; LYSOPHOSPHATIDYLCHOLINE; PROPRANOLOL; QUINAPRIL; QUINAPRILAT; SODIUM CHLORIDE; TRANDOLAPRIL; TRANDOLAPRILAT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYPOTONIC SOLUTION; INDOLE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ARTICLE; ATTENUATION; CELL DAMAGE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; LIPOPHILICITY; MICELLE; OSMOSIS; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; IN VITRO STUDY; METABOLISM;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEMOLYSIS; HUMANS; HYPOTONIC SOLUTIONS; INDOLES; LYSOPHOSPHATIDYLCHOLINES; MICELLES; PROPRANOLOL; SODIUM CHLORIDE; TETRAHYDROISOQUINOLINES;

EID: 1542439769     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.26.712     Document Type: Article

References (20)

1. Dostal D. E., Rothblum K. N., Conrad K. M., Cooper G. R., Baker K. M., Am. J. Physiol. 263, C851-C863 (1992).
2. Hafizi S., Wharton J., Morgan K., Allen S P., Chester A. H., Catravas J. D , Polak J. M., Yacoub M. H., Circulation, 98, 2553-2559 (1998).
3. Thomas J. M , Gordon H. W., Cir. Res., 51, 314-320 (1981).
4. Sobel B. E., Corr P. B., Robison A K., Goldstein R A., Witkowski F. X., Klein M. S., J. Clin. Invest., 62, 546-553 (1978).
5. Ma H , Hashizume H., Hara A., Yazawa K., Abiko Y., Jpn. J. Pharmacol., 79, 17-24 (1999).
6. Jeflery D. R , Charlton R. R., Venter J. C., J. Biol. Chem., 255, 5015-5018 (1980).
7. Anderson R., Ramafi G., Theron A. J., Biochem Pharmacol., 52, 341-349 (1996).
8. Ortner M. J., Sik R. H., Chignell C. F., Sokoloski E. A., Mol. Pharmacol., 15, 179-188 (1979).
9. Utsumi H., Inoue K., Nojima S , Kwan T., Biochemistry, 17, 1990-1996 (1978)
10. Weltzien H. U., Arnold B., Reuther R., Biochim. Biophys. Acta, 466, 411-421 (1977).
11. Bierbaum T. J., Bouma S. R., Huestis W. H., Biochim Biophys. Acta, 555, 102-110 (1979).
12. Cooper R. A , J Supramol Struct., 8, 413-430 (1978).
13. Ijzerman A. P., Nagesser A., Garritsen A., Biochem. Pharmacol., 36, 4239-4244 (1987).
14. Genes N., Lemoine G., Duguet A., Vaur L., Moreau G., Etriliard C., Soullier F., Thérapie, 50, 131-136 (1995).
15. Tanaka Y., Mashino K., Inoue K., J. Biochem. (Tokyo), 94, 833-840 (1983).
16. Rogers J. A., Cheng S., Betageri G. V., Biochem. Pharmacol., 35, 2259-2261 (1986).
17. Okunishi H., Pharm. Pharmacol. Lett., 2, 180-183 (1992).
18. Fabris B , Chen B , Pupic V., Perich R., Johnston C. I., J. Cardiovasc. Pharmacol , 15 (Suppl. 2), S6-S13 (1990).
19. Chevillard C., Brown N. L., Mathieu M. M., Laliberté F., Worcel M., Eur. J. Pharmacol., 147, 23-28 (1988).
20. Lüllmann H., Wehling M., Biochem. Pharmacol., 28, 3409-3415 (1979).